Udenafil

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Udenafil
Udenafil.svg
Clinical data
Routes of
administration
By mouth
ATC code
Legal status
Legal status
  • US: Not approved
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding 93,9%
Metabolism Liver (mainly CYP3A4)
Biological half-life 7.3–12.1 hours
Excretion Biliary
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
Formula C25H36N6O4S
Molar mass 516.657 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

The drug udenafil, marketed under the trade name Zydena, is within the PDE5 inhibitor class (which also includes avanafil, sildenafil, tadalafil, and vardenafil). Used, like other PDE5 inhibitors, to treat erectile dysfunction, udenafil was developed by Dong-A Pharmaceutical.[1] With action of fairly rapid onset (peak plasma concentration after 1 to 1.5 hours) yet long duration (plasma half life of 11 to 13 hours), udenafil's pharmacokinetics allows once-daily dosage (in addition to on-demand use).[2] Typical doses are 100 and 200 mg. Udenafil is available in Korea, Russia, and the Philippines;[3] in the United States, it has not been approved by the U.S. Food and Drug Administration.

References[edit]

  1. ^ Zydena (udenafil) product-information page. Dong-A Pharmaceutical. Retrieved on April 13, 2009.
  2. ^ "Udenafil: Efficacy and tolerability in the management of erectile dysfunction".
  3. ^ [http://www.drugs.com/international/zydena.html "Zydena", Drugs.com